Mankind Pharma Ltd
Mankind Pharma Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Expectation to outperform Indian Pharmaceutical Market (IPM) by about 1.2x in domestic revenue growth for FY '26. Guidance for EBITDA margins is maintained at 25%-26% overall; consumer healthcare currently has lower EBITDA margins (~20%) but is expected to scale up to company average.
From Mankind Pharma Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Expectation to outperform Indian Pharmaceutical Market (IPM) by about 1.2x in domestic revenue growth for FY '26.
- Chronic therapies projected to grow 1.2x to 1.3x the market, led by cardiac and anti-diabetic segments with consistent outperformance (1.5x and 1.3x IPM growth respectively).
- Consumer healthcare business anticipated to sustain strong growth, supported by recent successful product launches and improved presence in modern trade and e-commerce.
- BSV (super-specialty portfolio) expected to grow at 18% to 20% overall with international growth above 20%.
- International business saw 37% organic growth in FY '25; continuing growth is expected.
- Restructuring and integration efforts in acute segment expected to result in growth restarting from Q2 FY '26.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Mankind Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '25 capex spend increased to INR 531 crores, which is 4.3% of total revenue, in line with the guidance of 4% to 5% of revenue. (Page 7)
- The company continues R&D investments at approximately 2.5% to 3% of sales, aimed at building a strong portfolio and pipeline. (Page 11)
- Strategic focus on restructuring and integrating acquired businesses (e.g., BSV and TTK Rx businesses) to drive operational efficiency and growth. (Pages 8-10)
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Mankind Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Mankind Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.4K Cr, net profit ₹559 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Mankind Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Frequently Asked Questions
What were Mankind Pharma Ltd Q4 FY25 results?
Expectation to outperform Indian Pharmaceutical Market (IPM) by about 1.2x in domestic revenue growth for FY '26. Guidance for EBITDA margins is maintained at 25%-26% overall; consumer healthcare currently has lower EBITDA margins (~20%) but is expected to scale up to company average.
What is Mankind Pharma Ltd share price analysis?
Mankind Pharma Ltd currently shows a neutral. The stock trades at a P/E of 47.0 with a market cap of ₹100,160 Cr. Investors should review the full earnings analysis for detailed insights.
Is Mankind Pharma Ltd planning capital expenditure?
FY '25 capex spend increased to INR 531 crores, which is 4.3% of total revenue, in line with the guidance of 4% to 5% of revenue.
Keep Mankind Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.